Molecular screening of Smith-Lemli-Opitz syndrome in pregnant women from the Czech Republic
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- alely MeSH
- biochemie metody MeSH
- genotyp MeSH
- heterozygot MeSH
- komplikace těhotenství * MeSH
- lidé MeSH
- mutace MeSH
- mutační analýza DNA MeSH
- nesmyslný kodon MeSH
- plošný screening metody MeSH
- riziko MeSH
- Smithův-Lemliho-Opitzův syndrom diagnóza genetika MeSH
- těhotenství MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- nesmyslný kodon MeSH
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive metabolic disorder. SLOS is caused by the mutations in the gene for 3beta-hydroxysterol Delta(7) reductase (DHCR7; EC 1.3.1.21), which maps to chromosome 11q12-13. DHCR7 catalyses the final step in cholesterol biosynthesis-the reduction of 7-dehydrocholesterol to cholesterol. Clinical severity ranges from mild dysmorphism to severe congenital malformation and intrauterine lethality. Pregnant women are offered a biochemical screening test for Down syndrome in the second trimester, where the suspicion for SLOS could be registered, when the unconjugated estriol (uE3) level appears low. A group of 456 fetuses with a high risk for SLOS were examined by DNA analysis. We confirmed SLOS in 5 fetuses and 11 fetuses were carriers. One novel mutation (p.G30A) was detected. The most frequently found mutations, c.964-1G > C and p.W151X, are also the most severe ones. At least one of these mutations was detected in each fetus with SLOS. This suggests that the biochemical screening of pregnant women probably uncovers mainly more severely affected fetuses. We confirmed SLOS also in two patients whose prenatal screening was negative. Both of them had nonsense mutation on one allele. It stands to reason that some modifying factors may play a role in the reduction of the uE3 level in the mother's serum.
Zobrazit více v PubMed
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1899-902 PubMed
Am J Med Genet. 2000 Jan 31;90(3):260 PubMed
Lancet. 1993 May 29;341(8857):1414 PubMed
Am J Med Genet. 1999 Feb 19;82(5):376-81 PubMed
Mol Genet Metab. 2005 Feb;84(2):112-26 PubMed
J Med Screen. 2002;9(1):43-4 PubMed
Am J Hum Genet. 1998 Jul;63(1):55-62 PubMed
Am J Hum Genet. 1998 Aug;63(2):322-6 PubMed
Prenat Diagn. 1998 Aug;18(8):789-800 PubMed
Clin Genet. 2001 Jun;59(6):375-86 PubMed
Hum Mutat. 2001 Mar;17(3):172-82 PubMed
Biochim Biophys Acta. 2000 Dec 15;1529(1-3):340-56 PubMed
Prenat Diagn. 2002 Sep;22(9):827-30 PubMed
Am J Med Genet. 2000 Sep 18;94(3):214-27 PubMed
N Engl J Med. 1994 Jan 13;330(2):107-13 PubMed
J Inherit Metab Dis. 2000 Jun;23(4):409-12 PubMed
J Pediatr. 1964 Feb;64:210-7 PubMed
Am J Obstet Gynecol. 1997 Mar;176(3):531-5 PubMed
Curr Opin Lipidol. 1999 Apr;10(2):123-31 PubMed
Am J Med Genet A. 2005 Sep 15;138(1):61-5 PubMed
Nat Genet. 2003 Apr;33(4):508-13 PubMed
J Pediatr. 1995 Jul;127(1):82-7 PubMed
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8181-6 PubMed
Mol Genet Metab. 2000 Sep-Oct;71(1-2):163-74 PubMed
Eur J Hum Genet. 2001 Jan;9(1):45-50 PubMed
Hum Mol Genet. 2000 May 22;9(9):1385-91 PubMed
Am J Obstet Gynecol. 1997 May;176(5):1046-51 PubMed
Am J Hum Genet. 2000 Feb;66(2):402-12 PubMed
Hum Genet. 1995 Oct;96(4):472-6 PubMed
Prenat Diagn. 2006 Sep;26(9):842-9 PubMed
Am J Med Genet. 1999 Feb 12;82(4):355-8 PubMed
Am J Med Genet. 1997 Jan 31;68(3):251-6 PubMed
Science. 1996 Oct 11;274(5285):255-9 PubMed
J Med Genet. 1998 Jul;35(7):558-65 PubMed
